1-Amino-3-[2-(4-ethoxyphenyl)ethyl]-4-(4-methoxyphenyl)imidazolidin-2-one | 1192408-10-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 英文名称: 1-Amino-3-[2-(4-ethoxyphenyl)ethyl]-4-(4-methoxyphenyl)imidazolidin-2-one
• CAS: 1192408-10-8
• 化学式: C₂₀H₂₅N₃O₃
• 分子量: 355.437
• InChiKey: XWBQXTQOXAWUAN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  68
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-Amino-3-[2-(4-ethoxyphenyl)ethyl]-4-(4-methoxyphenyl)imidazolidin-2-one 、 甲基磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 0.75h， 以68%的产率得到1-(methylsulfonylamino)-3-[3-(4-ethoxyphenyl)propyl]-4-(4-methoxyphenyl)-2-imidazolidinone
  参考文献：
  名称：

  Selective Kv1.5 Blockers: Development of (R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia

  摘要：

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

  DOI：

  10.1021/jm901042m
• 作为产物：
  描述：

  在 溶剂黄146 、 锌 作用下， 以 水 为溶剂， 生成 1-Amino-3-[2-(4-ethoxyphenyl)ethyl]-4-(4-methoxyphenyl)imidazolidin-2-one
  参考文献：
  名称：

  Selective Kv1.5 Blockers: Development of (R)-1-(Methylsulfonylamino)-3-[2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl)-2-imidazolidinone (KVI-020/WYE-160020) as a Potential Treatment for Atrial Arrhythmia

  摘要：

  Atrial fibrillation is the most prevalent form of cardiac arrhythmia. Current treatments extend the atrial effective refractory period by nonselective blockade of cardiac ion channels. An alternative approach selectively targeting the Kv1.5 ion channel offers the opportunity for therapeutic benefit with decreased risk of adverse cardiovascular events. KVI-020 (4g) successfully demonstrated antiarrhythmic efficacy in a canine arrhythmia model, and these findings support its utility as an antiarrhythmic agent.

  DOI：

  10.1021/jm901042m